GDF8 inhibitor (Rigel Pharmaceuticals)

N/A

Report date: 2025/02/01 20:00:06

NME

Base Information

Drug NameGDF8 inhibitor (Rigel Pharmaceuticals)

Drug Alias NameACVR2B program (Rigel Pharmaceuticals)activin type IIB receptor antagonist (Rigel Pharmaceuticals)Growth Differentiation Factor 8 Inhibitors (Rigel Pharmaceuticals)

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionGrowth/differentiation factor 8 inhibitorsActivin receptor type-2B inhibitors

TargetsActivin receptor type-2BGrowth/differentiation factor 8

Therapy Area/IndicationsMuscular Atrophy

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesRigel Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesRigel Pharmaceuticals Inc

Active IndicationsN/A

Inactive IndicationsMuscular Atrophy

Other Information

ATC CodeN/A